Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Mar 2023Metachromatic Leukodystrophy
Sep 2023Non-Alcoholic Steatohepatitis
Apr 2023Pulmonary Arterial Hypertension
Dec 2023Sickle Cell Disease
Jul 2023Featured News & Insights.
Learn about our latest work.
ICER Publishes Final Evidence Report on Treatments for Non-Alcoholic Steatohepatitis
Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net health benefit over lifestyle management, whereas current evidence for obeticholic acid was deemed inadequate to demonstrate a net health benefit.
05/25/2023ICER to Assess Treatment for Pulmonary Arterial Hypertension
— Report will be subject of Midwest CEPAC meeting in December 2023; Draft Scoping Document open to public comment until June 5, 2023 —
05/15/2023ICER Collaborates with International Partner Agencies to Streamline the Confidential Marking Process
ICER, CADTH and NICE have collaborated on a more consistent approach to handling clinical data
04/24/2023Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Latest
Developments.
In 2021, we celebrated our 15th anniversary! Learn more.
ICER recently collaborated with NICE and CADTH on HTA methods. Learn more.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change
Unsupported Price Increases
Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.